Oncophage approved in Russia for kidney cancer
NEW YORK-Antigenics Inc.’s personalized cancer vaccine Oncophage (vitespen) has received its first government approval.
NEW YORK-Antigenics Inc.’s personalized cancer vaccine Oncophage (vitespen) has received its first government approval. The Russian Ministry of Public Health has certified its use in kidney cancer patients at intermediate risk for disease recurrence, based on data from 604 patients showing a significant improvement in recurrence-free survival with Oncophage vs observation.
Derived from each individual’s tumor, Oncophage contains the “antigenic fingerprint” of the patient’s particular cancer and is designed to reprogram the body’s immune system to target only cancer cells bearing this fingerprint.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
